title: The chemosensitivity to therapy of childhood early B acute lymphoblastic leukemia could be determined by the combined expression of CD34, SPI-B and BCR genes.
abstract: We have identified genes differentially expressed in childhood early B acute lymphoblastic leukemia at diagnosis, according to chemosensitivity. Chemosensitive (M1) and chemoresistant (M3) patients present <5% and >25% of residual leukemic blasts at 21 days of treatment, respectively. The expression profiles of 4205 genes for 32 patients included in the FRALLE93 protocol have been determined using microarray. From differential analysis, CD34, SPI-B and BCR distinguished M1 from M3 patients using microarray and RT-PCR data. Linear discriminant analysis (LDA) and cross-validation show that the combined expression of these three genes classify and predict correctly around 90% and 80% of patients, respectively.
authors.affiliation: Centre d'Immunologie de Marseille-Luminy (CIML), CNRS-INSERM-Univ. Méditerranée, Campus de Luminy, Case 906, 13288 Marseille Cedex 09, France.
authors.forename: Leila
authors.initials: L
authors.lastname: Talby
authors.forename: Hervé
authors.initials: H
authors.lastname: Chambost
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Roubaud
authors.forename: Catherine
authors.initials: C
authors.lastname: N'Guyen
authors.forename: Michèle
authors.initials: M
authors.lastname: Milili
authors.forename: Béatrice
authors.initials: B
authors.lastname: Loriod
authors.forename: Chantal
authors.initials: C
authors.lastname: Fossat
authors.forename: Christophe
authors.initials: C
authors.lastname: Picard
authors.forename: Jean
authors.initials: J
authors.lastname: Gabert
authors.forename: Pierre
authors.initials: P
authors.lastname: Chiappetta
authors.forename: Gérard
authors.initials: G
authors.lastname: Michel
authors.forename: Claudine
authors.initials: C
authors.lastname: Schiff
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage; D018952:Antigens, CD34 / Q000096:biosynthesis* / Q000235:genetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001215:Asparaginase / Q000008:administration & dosage; D001752:Blast Crisis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D002051:Burkitt Lymphoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003348:Cortisone / Q000008:administration & dosage; D004268:DNA-Binding Proteins / Q000096:biosynthesis* / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods; D015973:Gene Expression Regulation, Leukemic / Q000235:genetics; D006801:Humans; D007223:Infant; D008297:Male; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D011237:Predictive Value of Tests; D051562:Proto-Oncogene Proteins c-bcr / Q000096:biosynthesis* / Q000235:genetics; D014157:Transcription Factors / Q000096:biosynthesis* / Q000235:genetics; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018943:Anthracyclines; D018952:Antigens, CD34; D004268:DNA-Binding Proteins; D014157:Transcription Factors; C076877:SPIB protein, human; D014750:Vincristine; C496613:BCR protein, human; D051562:Proto-Oncogene Proteins c-bcr; D001215:Asparaginase; D003348:Cortisone